Conferences

Inspired by his son’s battle with cancer, Neal Piper founded Luminoah to modernize enteral feeding. Its smart, pocket-sized pump tracks nutrition in real time to prevent malnutrition and improve quality of life for patients and caregivers.

John Nugent, who heads the medtech division at Irish business development agency IDA Ireland, spoke to Medtech Insight about how the country’s 75-year focus on encouraging medtech innovation is shifting in the light of digital health, AI, tariffs, and other new challenges.

Google Cloud healthcare lead Shweta Maniar talked with Medtech Insight about improving health monitoring, boosting regulatory collaboration, and deepening integration of technology in medical practices.

Some of the first manufacturers to receive Medicare coverage for their breakthrough devices through the Transitional Coverage for Emerging Technologies pathway praise CMS’ engagement and timelines in the process, despite some challenges around post-launch data collection.

During CES 2025, Medtech Insight accompanied Deloitte analysts Neal Batra and Andrew Davis to identify the biggest trends in digital health and solutions poised to transform the future of health care. Key trends included empowering consumers with actionable health data, the rising investment in specialized areas such as women’s health, and more companies pursuing regulatory clearance for health products.

In this second roundup of innovative technologies seen or demoed at CES 2025, Medtech Insight tunes into heartbeat-listening earbuds, vision aids for people with macular degeneration, UTI-detecting toilets, non-invasive injection devices, hot flash-cooling wristband, mobility-aiding smart shoes, and robotic aids for cerebral palsy.

In this first of a two-part series from CES, Medtech Insight tunes into two companies that developed AI-powered cameras to detect respiratory diseases and chronic diseases respectively, two companies offering at-home testing for cholesterol, and a saliva test to help detect symptoms of perimenopause.

Medtech Insight brings you the highlights from two panel discussions at CES 2025 featuring innovators in the neurotech space discussing opportunities, challenges and ethical considerations in developing AI-driven solutions for the brain, and what lies ahead.

Digital therapeutics aren’t going away anytime soon, but they are positioning themselves as a complement to traditional therapies.

At the recent Precision Med-Tri Con conference, laboratory experts traded views on the expansion of at-home testing for disease diagnosis and personalized health insights. While strong consumer demand spells opportunity, there are significant concerns about the accuracy and reliability of home-testing platforms, misuse, accessibility, and lack of health literacy.

Public and private payors at the Digital Therapeutics Alliance’s 2023 Inaugural Summit weighed in on the coverage environment for prescription digital therapeutics post-Pear Therapeutics and strategic moves companies can make to position themselves advantageously.

A panel discussion between health professionals, industry groups and digital therapeutics innovators at the DTA Summit highlighted opportunities and barriers for the development and adoption of digital therapeutics.

In this week’s Digital Health Roundup, Medtech Insight’s Marion Webb highlights her conference coverage from CES, HIMSS, AAOS and LSI including Exec Chats with Gary Guthart, CEO of Intuitive Surgical, and Arcadia’s chief strategy officer Aneesh Chopra. Brian Bossetta highlights a recently FDA-cleared alert system that sends vital signs to clinicians. Elizabeth Orr discusses FDA warning letters sent to Exer Labs for exceeding marketing claims under what is allowed under the device’s 510(k) clearance. Shubham Singh discusses how Roche's unveiling of its next-generation sequencing (NGS) prototype challenges Illumina. The SBX technology is set to compete directly with Illumina’s NovaSeq and NextSeq platforms.

Medtech Insight sat down with Arcadia's chief strategy officer Aneesh Chopra to discuss interoperability, industry standards and the future of health care data and AI.

During a panel discussion at HIMSS, experts highlighted the shift in digital health funding in 2024 with “mega funds” dominating the space and big tech companies developing foundational models that large health care customers use to address multiple use cases. They noted, however, there is ample room for smaller companies to develop technologies adjacent to incumbent systems.

Google Cloud launches new generative AI capabilities in Vertex AI for health care, allowing clinicians to gain access to multimodal data such as images and data to help with decision-making.

Viome Life Sciences accelerates its push into clinical diagnostics with studies in colorectal cancer and a major partnership with Microsoft to scale its molecular data analysis platform. Viome leverages RNA analysis and AI to detect disease at the molecular level and personalize preventive health.

Delfi Diagnostics is preparing for pivotal trial results that could support FDA approval and reimbursement for its fragmentomics-based lung cancer screening test. Early data suggest strong potential to improve screening uptake and expand access to early detection.

After rolling out its hair-based autism diagnostic across the US, LinusBio is expanding into Japan and testing its “molecular movie” technology for ALS and other neurological disorders, aiming to deliver the first objective biomarkers in pediatric and neuropsychiatric care.

Astrin Biosciences will debut Certitude, a proteomics-based blood test for women with dense breasts, aiming to detect early breast cancer with MRI-like accuracy and outperform current supplemental imaging.

Becton Dickinson is investing in high-growth segments and is on a mission to simplify its business. CEO Tom Polen’s 2025 strategy targets 25% operating margin from both innovations and durable core business combined, as senior BD executives told In Vivo during a break at J.P. Morgan 2024.

Exec Chat: Dexcom’s COO Jake Leach joined a panel discussion on the future of biosensing at CES 2024, where biowearables and glucose tech ranked among hot topics. He also spoke to Medtech Insight about plans for the company’s new CGM called Stelo, designed for people with type 2 diabetes who do not use insulin, Dexcom’s work with Apple to enable CGM users, and non-invasive monitoring prospects.

Exec Chat: UK consumer feedback has led to enhancements to the Lingo biowearable’s companion app to provide deeper, more personalized insight on the meaning of glucose spikes, as well as weeklong challenges to encourage healthy behavioral changes. While awaiting FDA clearance for a planned 2024 launch of Lingo stateside, Abbott also is exploring ways of accessorizing the Lingo sensor to make it more fashionable. Lingo Biowearables leaders Olivier Ropars and Ben Fohner discuss.

Medtech Insight covered the major announcements from medtech companies during the J.P. Morgan Healthcare Conference in early January. Here are a few more highlights from companies that may not have made the headlines but will, no doubt, make noise in 2024.